Isolation of a Novel Phage with Activity against Streptococcus mutans Biofilms
Marion Dalmasso, Eric de Haas, Horst Neve, Ronan Strain, Fabien Cousin, Stephen Stockdale, R. Paul Ross, Colin Hill

To cite this version:
Marion Dalmasso, Eric de Haas, Horst Neve, Ronan Strain, Fabien Cousin, et al.. Isolation of a Novel Phage with Activity against Streptococcus mutans Biofilms. PLoS ONE, Public Library of Science, 2015, 10 (9), pp.e0138651. 10.1371/journal.pone.0138651. hal-02166895

HAL Id: hal-02166895
https://hal-normandie-univ.archives-ouvertes.fr/hal-02166895
Submitted on 27 Jun 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Isolation of a Novel Phage with Activity against *Streptococcus mutans* Biofilms

Marion Dalmasso¹,², Eric de Haas¹,², Horst Neve³, Ronan Strain¹,², Fabien J. Cousin¹,², Stephen R. Stockdale²,⁴, R. Paul Ross¹,², Colin Hill¹,²*

¹ School of Microbiology, University College Cork, Cork, Ireland, ² APC Microbiome Institute, University College Cork, Cork, Ireland, ³ Department of Microbiology and Biotechnology, Max Rubner-Institut, Kiel, Germany, ⁴ Teagasc Biotechnology Centre, Moorepark Food Research Centre, Fermoy, Co. Cork, Ireland

* c.hill@ucc.ie

**Abstract**

*Streptococcus mutans* is one of the principal agents of caries formation mainly, because of its ability to form biofilms at the tooth surface. Bacteriophages (phages) are promising antimicrobial agents that could be used to prevent or treat caries formation by *S. mutans*. The aim of this study was to isolate new *S. mutans* phages and to characterize their antimicrobial properties. A new phage, φAPCM01, was isolated from a human saliva sample. Its genome was closely related to the only two other available *S. mutans* phage genomes, M102 and M102AD. φAPCM01 inhibited the growth of *S. mutans* strain DPC6143 within hours in broth and in artificial saliva at multiplicity of infections as low as 2.5×10⁻⁵. In the presence of phage φAPCM01 the metabolic activity of a *S. mutans* biofilm was reduced after 24 h of contact and did not increased again after 48 h, and the live cells in the biofilm decreased by at least 5 log cfu/ml. Despite its narrow host range, this newly isolated *S. mutans* phage exhibits promising antimicrobial properties.

**Introduction**

The microbiome of the human oral cavity is composed of numerous and diverse bacteria, archaea, eukaryotes and viruses [1–3]. Dental caries arise as a result of an ecological imbalance of metabolic activities in the stable oral microbiome. Dental caries is one of the most prevailing and persistent disease in the human population, despite the availability of various prophylactic options. *Streptococcus mutans* is a Gram-positive, coccus-shaped, non-motile and facultative anaerobic bacterium which is naturally present in the human mouth. It is an opportunistic pathogen and the principal etiological agent of dental decay in humans. *S. mutans* is able to adhere to the tooth surface in biofilm communities that contribute to dental plaque and favour the progression of dental disease [4, 5]. Within the dental plaque, *S. mutans* contributes greatly to the composition of the biofilm matrix, especially by producing abundant exopolysaccharides (EPS) [6]. *S. mutans* pathogenicity also results from its acidogenicity in the presence of dietary sucrose and its concomitant acid tolerance, both of which support changes in the ecology of the dental plaque by selecting for a cariogenic flora, increasing the probability of enamel demineralization and eventually caries formation [7]. When established as a biofilm, microbial
communities are less sensitive to conventional antimicrobial interventions and, in any event, antibiotics are not favoured as a means of controlling or preventing caries.

Bacteriophage (phage) therapy is increasingly considered as a potential alternative to antibiotic treatments [8]. Phages are bacterial viruses that can attack and kill a target bacterium within minutes of infection. They are self-replicating and generally only target a narrow range of bacterial strains of the same species. Phages have been used in clinical settings for decades and are now accepted to be effective for the control of pathogenic bacteria in food [9]. Commercial phage cocktails, such as ListShield™ and LISTEX™ P100, are used against Listeria monocytogenes in the food industry and have obtained Generally Recognized As Safe (GRAS) status from the FDA [10]. While phages have been extensively used in some countries of Eastern Europe for clinical purposes, there are still no approved phage treatments in the Western world for clinical use [10]. However, promising research is being conducted on phages to treat bacterial pathogens such as Pseudomonas aeruginosa [11], enteroaggregative Escherichia coli [12], Clostridium difficile [13] and methicillin-resistant Staphylococcus aureus [14]. By discovering new phages effective against pathogenic bacteria, it is possible to develop alternative treatment methods to antibiotics. A few studies exist regarding the use of phages for curing dental infections with various pathogens such as Enterococcus faecalis [15], Fusobacterium nucleatum [16] and P. aeruginosa [17]. To our knowledge, no study has been dedicated to the use of phages to control S. mutans growth and biofilm formation. Relatively little is known about S. mutans phages. To date only two S. mutans phage genomes, M102 and M102AD, are available in public databases [18, 19]. Two other S. mutans phages, e10 and f1, have previously been isolated and tested for their host range and morphology, without being sequenced [20]. The aim of the current study was to isolate and characterize new S. mutans phages from saliva samples, and to test their efficacy in reducing S. mutans growth and biofilm formation for potential future application as antimicrobial agents.

**Materials and Methods**

**Strains and culture conditions**

*S. mutans* strains (Table 1) were grown overnight in BHI broth (Oxoid, Basingstoke, United Kingdom) at 37°C under aerobic conditions. All strains originated from the collection of Moorepark Food Research Centre (Ireland). Strain serotypes were checked using a PCR method described previously [21] (Table 1).

**Human subject enrolment**

Subject recruitment and enrolment were approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals (protocol no. APC052). All subjects completed a questionnaire demonstrating their willingness to participate in the study. All subjects were healthy adults without known oral health problems. A minimum of 3 ml of saliva was collected in the morning before breakfast prior to any oral hygiene practices, and the saliva was analysed within 2 h after collection. A total of 85 samples were collected.

**Phage isolation from human saliva**

One millilitre of saliva was centrifuged at 8000xg for 10 min, before being sterilised using 0.45 μm filters. Saliva filtrates were kept at 4°C. For each sample, 100 μl of saliva filtrate were mixed with 200 μl of bacterial overnight culture, and incubated for 20 min at 37°C. The indicator *S. mutans* strains used were DPC6143, DPC6144, DPC6145, DPC6150, DPC6151 and DPC6152 (Table 1). The filtrate-bacteria mixture was then added to 3 ml of soft BHI agar
(0.5% agar w/v) containing 10 mM CaCl₂, and overlaid on top of a BHI agar plate. Plates were incubated for a minimum of 24 h at 37°C or until plaques could be detected.

**Electron microscopic analysis**

Phage lysates were purified on a caesium chloride gradient by ultracentrifugation, and were dialyzed against phage buffer (20 mM Tris-HCl [pH 7.2], 10 mM NaCl, 20 mM MgSO₄) overnight at 4°C. Negative staining of phages and transmission electron microscopic analysis were as previously described [22].

**One-step growth curve**

A one-step growth experiment was performed in triplicate to assess the burst size, and latency and rise phases of phage ΦAPCM01 using a method previously described [22] with the following modifications. Incubations were performed in BHI broth supplemented with 10 mM CaCl₂, at 37°C. A multiplicity of infection (MOI) of 1 was used.

**Efficiency of lysogeny**

Efficiency of lysogeny was assessed as previously described [23]. Briefly, 100 μl of 10¹⁰ pfu/ml phage lysate were spread onto BHI agar plates. An overnight culture of *S. mutans* DPC6143 strain was diluted by serial 1:10 dilutions. For 10⁻⁴ to 10⁻⁷ dilutions, 100 μl were mixed with 4 ml of sloppy BHI agar (0.5% agar) supplemented with 10 mM CaCl₂, and overlaid onto phage seeded plates and phage-free control plates. The plates were incubated at 37°C for 24 h. Cfu numbers were count on countable plates, considering that the colonies growing on phage seeded plates were all lysogens. The percentage of efficiency of lysogeny was calculated as

---

**Table 1. *Streptococcus mutans* strains used in this study.**

| Strain No. | Origin | Serotype | Source and reference |
|-----------|--------|----------|----------------------|
| DPC6143   |        | e        |                      |
| DPC6144   |        | e        |                      |
| DPC6145   |        | c        |                      |
| DPC6150   |        | c        |                      |
| DPC6151   |        | c        |                      |
| DPC6152   |        | c        |                      |
| DPC6153   | Dental saliva isolate from University College Cork dental hospital | c | Culture collection of Moorepark Food Research Centre (Ireland) [48] |
| DPC6154   |        | c        |                      |
| DPC6155   |        | c        |                      |
| DPC6156   |        | c        |                      |
| DPC6157   |        | c        |                      |
| DPC6158   |        | c        |                      |
| DPC6159   |        | e        |                      |
| DPC6160   |        | c        |                      |
| DPC6161   |        | c        |                      |
| DPC6162   | Carious dentine | e | Type strain NCTC10449 |
| DPC6543   | NA     | c        | University of Toronto |

NA: not available

doi:10.1371/journal.pone.0138651.t001
follows: (cfu on phage seeded plates / cfu on phage-free control plates) x 100. All experiments were performed in triplicate.

**Bacterial challenge and artificial saliva assays**

Bacterial challenge and kill-curve assays were performed to determine the effect of different MOI’s of phage on *S. mutans* survival. An overnight culture of *S. mutans* DPC6143 strain was diluted in 2× GM17 broth (Oxoid) containing 20 mM CaCl₂ to reach 10⁴ cfu/ml. The wells of a 96-well microplate were filled with 100 μl of the diluted culture. Serial 1:10 dilutions of the phage lysate were performed in phage buffer. The eight wells of each column of the 96-well microplate containing the diluted culture were filled with 100 μl of the same phage dilution. The range of MOI’s tested was between 2.5x10⁻⁵ and 2.5x10². One column of the plate contained positive control wells with only 100 μl of the diluted *S. mutans* culture and 100 μl of phage buffer. Another column contained only 100 μl of 2× GM17 broth and 100 μl of phage buffer. The plate was incubated at 37°C for 18 h. Optical density (OD₆₀₀nm) measures were taken and a Student’s t-test was performed to assess significance (GraphPad, Prism, version 5.03). Bacterial counts were performed in triplicate for each condition tested using the enumeration miniaturized method described previously [24].

Kill-curves were performed as described for the bacterial challenge assay, with OD₆₀₀nm measures recorded every 15 min using an MWGt Sirius HT plate reader (BIO-TEK Instruments, USA).

The action of phages on *S. mutans* DPC6143 strain was also tested in artificial saliva [25] supplemented with 1% sucrose. An overnight culture of *S. mutans* DPC6143 strain was centrifuged at 8000×g for 10 min at room temperature. The supernatant was discarded and the pellet was resuspended in the same volume of 2x artificial saliva. The same method as for the bacterial challenge described above was applied to assess the action of phage against *S. mutans* in artificial saliva.

**Biofilm assays**

Two 96-well plates were filled as followed. Each well was filled with 200 μl of BHI broth inoculated at 1% with an overnight culture of strain DPC6143. The plates were incubated at 37°C for 48 h to allow the biofilm to form. Broth containing planktonic cells was removed, being careful not to disturb the cells attached to the wells. 100 μl of 2× BHI broth containing 20 mM CaCl₂ and 100 μl of lysate dilutions as describe above were added to each well. Phage lysate concentrations from 10² to 10⁹ phage per well were tested, with each phage concentration being tested in 8 wells of the plate. The positive and negative controls were performed as described above. One plate was incubated at 37°C for 24 h and the other at 37°C for 48 h. After incubation, the wells were emptied carefully and gently washed with phosphate buffered saline. A colorimetric assay using XTT and menadione as previously described [26] was performed to assess the metabolic activity of *S. mutans* biofilm after phage treatment. Bacterial counts were performed in triplicate for each condition tested. Briefly, biofilms were detached from the wells by thorough mixing by pipetting with 200 μl maximum recovery diluent (Oxoid), and counts were carried out following the enumeration miniaturized method [24].

**DNA extraction and genome sequencing**

DNA was extracted from the CsCl purified fractions [22]. Briefly, 400 μl of the CsCl purified fraction were treated with 6 U Ambion TURBO DNase (Life technologies, USA). After DNase treatment, 4 μl of proteinase K (20mg/ml) and 30 μl of 10% SDS were added and followed by an incubation step of 1h at 56°C. Another incubation step of 10 min at 65°C followed...
after the addition of 70 μl 5 M NaCl and 100 μl of phage lysis buffer (4.5 M guanidine thiocyanate, 44 mM sodium citrate [pH 7.0], 1% sarkosyl, 72 μl 2-mercaptoethanol). DNA was then extracted and purified using phenol:chloroform:isoamyl alcohol (25:24:1, Sigma-Aldrich, Saint-Louis, USA), and precipitated with ice-cold ethanol. DNA samples were sent to GATC (Konstanz, Germany) for whole phage genome sequencing using an Illumina HiSeq 2500 sequencer with 2x100 bp read length. The reads generated by the Illumina instrument were assembled at GATC.

**In silico genome analysis**

Protein-encoding open reading frames (ORFs) were predicted using Glimmer [27] and the RAST server [28]. Initial functional annotation of the ORFs and percentage amino acid identities were determined using BLASTP [29]. Phylogenetic trees were constructed using streptococcal endolysin amino acid sequences which gave the highest possible identity percentage with endolysins in phage ɸAPCM01 genome. The evolutionary history was inferred by using the Maximum Likelihood method based on the JTT matrix-based model [30] in MEGA 6 [31]. The bootstrap consensus tree inferred from 1000 replicates was taken to represent the evolutionary history of the taxa analysed [32]. Branches corresponding to partitions reproduced in less than 50% bootstrap replicates were collapsed. Initial tree(s) for the heuristic search were obtained by applying the Neighbor-Joining method to a matrix of pairwise distances estimated using a JTT model.

**Accession number**

The complete genome sequence of ɸAPCM01 has been deposited in GenBank under accession number KR153145.

**Results**

**Morphology, host range, population dynamics, and lysogeny**

Given the potential of phage therapy, a screening of 85 saliva samples was performed to isolate *S. mutans* phage. A single *S. mutans* phage, ɸAPCM01, was isolated from one saliva sample. ɸAPCM01 belongs to the (small-isometric headed) *Siphoviridae* family with B1 morphology as shown by electron microscopy (Fig 1). The head diameter was 54.6 ± 1.0 nm (n = 7) and the length of the non-contractile and flexible tail was 278.0 ± 9.7 nm (n = 7). Small baseplate structures (width: 16.1 ± 0.8 nm [n = 7]) without further appendices or fibers were visible at the distal end of the tails (tail width: 11.5 ± 0.4 nm [n = 7]). Of the 17 *S. mutans* strains tested ɸAPCM01 targeted only strain DPC6143.

A one-step growth curve was performed to assess the population dynamics of ɸAPCM01 in the presence of *S. mutans* strain DPC6143. ɸAPCM01 had a latent period of 60 min and a rise phase of 60 min before reaching the plateau phase (Fig 2). The burst size was calculated as 44.2 ± 9.8 phage particles.

Lysogeny of phage ɸAPCM01 was assessed against *S. mutans* strain DPC6143. The numbers of bacteria on phage seeded plates and on phage-free control plates were 5.7 ± 0.2 and 9.3 ± 0.09 log cfu/ml, respectively. This gave a mean efficiency of lysogeny of 0.027 ± 0.007%.

**Bacterial challenge**

The ability of ɸAPCM01 to reduce or prevent the growth of *S. mutans* DPC6143 was assessed after 18 h of contact with the phage at MOI’s ranging from 2.5x10⁻⁵ to 250 (Fig 3A). A significant decrease in OD₆₀₀nm of at least 2-fold between the control culture and the cultures with
added phages was observed for all the tested MOI’s (p-value<0.001). This indicates that the phage was efficient even at a low MOI. This was confirmed by a decrease of at least 5.6 log cfu/ml between the control culture and the cultures with added phages at MOI’s smaller than 2.5x10^{-3} (Fig 3A). At MOI’s higher than 2.5x10^{-2} no colonies could be detected (detection threshold of 20 cfu/ml). φAPCM01 prevented the growth of S. mutans DPC6143 at MOI’s higher than 2.5x10^{-2} or reduced its growth at lower MOI’s.

Kill curves confirmed this result and indicated that S. mutans DPC6143 was inhibited by φAPCM01 at an early stage of growth (Fig 3B). At MOI’s higher than 10^{-2}, no growth occurred as OD_{600nm} values remained the same as the sterile medium OD_{600nm} values during the entire incubation period. At MOI’s equal to, or less than, 10^{-3}, some growth initially occurred but the OD declined after 7 to 10 hours of incubation.

The lytic activity of φAPCM01 against S. mutans DPC6143 strain was also assessed in artificial saliva (Fig 3C). The OD_{600nm} decreased by at least 1.5 fold compared to the control culture without phage. Bacterial counts revealed that a significant reduction of about 3.6 log cfu/ml (p-value<0.05) was only observed between the highest tested MOI and the control. Even if the decrease was less dramatic in artificial saliva than in culture broth, the phage could still reduce S. mutans DPC6143 growth in artificial saliva.
Action of phage against biofilms

Phage φAPCM01 was tested against 48 h-attached \textit{S. mutans} DPC6143 cells in 96-well plates (Fig 4). After phage treatment, the metabolic activity of the biofilm was assessed using XTT assays and the numbers of live cells were quantified by bacterial counts. With initial doses equal to or higher than 10^2 pfu/well, φAPCM01 significantly reduced the biofilm activity within 24 h of contact (p-value < 0.001, Fig 4A). At doses ranging from 10^5 to 10^9 pfu/well, phage φAPCM01 completely inhibited the biofilm metabolic activity as shown by OD_{492nm} values close to 0.2, the OD value of the medium alone. At phage doses between 10^2 and 10^4 pfu/well, OD_{492nm} Values were lower compared to the control but high enough to indicate residual metabolic activity of \textit{S. mutans}. At these doses, phage φAPCM01 could reduce the biofilm but not completely disrupt it. Bacterial counts confirmed the reduction of the biofilm biomass due to phage action after 24 h of contact (Fig 4B). A difference of at least 5 log cfu/ml was noticeable between the control biofilm and the biofilm in the presence of phage doses higher than 10^5 pfu/well (Fig 4B). A difference of 1, 1.8 and 3.5 log cfu/ml was measured between the control and the biofilm at phage doses of 10^2, 10^3 and 10^4 pfu/well, respectively (Fig 4B).

After 48 h of contact with phage φAPCM01, the biofilm metabolic activity measured by XTT was significantly reduced at phage doses of 10^5, 10^6 and 10^9 pfu/well compared to the 24 h-incubation step (p-value < 0.005) (Fig 4A). For these doses, OD_{492nm} was close to the OD_{492nm} of the medium. At phage doses of 10^2 and 10^5 pfu/well, no significant changes in the OD_{492nm} values were observed after 48 h of contact with phage compared to the 24 h-incubation step, indicating the absence of biofilm development. At phage doses ranging from 10^6 to 10^9 pfu/well, no significant differences in the number of bacterial cells between 24 h and 48 h of contact with the phage were noticeable (p-value > 0.05, Fig 4B). This indicated that phage φAPCM01 is able to control the growth of the \textit{S. mutans} biofilm. An increase of 0.6 log cfu/ml
A New Phage against S. mutans Biofilm

(a)

(b)

(c)
at a phage dose of $10^4$ pfu/well was visible ($p < 0.05$) after 48 h. A decrease of 0.7 log cfu/ml at phage doses of $10^5$ and $10^3$ pfu/well was also noticeable (Fig 4B).

**Genome features and comparison with S. mutans phage M102 and M102AD genomes**

The complete genome size of phage $\phi$APCM01 is 31,075 bp with a G-C content of 39%. A total of 37 ORFs were identified on the same strand and 23 could be assigned a putative function. No tRNA encoding regions were found in $\phi$APCM01’s genome. The $\phi$APCM01 genome compares closely with two other S. mutans phage genomes and is organized into the following functional modules: DNA packaging, morphogenesis, lysis, and DNA replication and recombination (Fig 5). $\phi$APCM01 shares 85% identity with M102 and M102AD at the nucleotide level. However, some discrepancies in the number of ORFs exists between the three phages. ORF31, encoding a protein of unknown function, is only present in the $\phi$APCM01 genome while four ORFs which are present in the other phage genomes (M102 ORF34, ORF37, ORF40, ORF41) are missing in $\phi$APCM01 (Fig 5). All these ORFs are located in the replication module and encode proteins of unknown function.

The maximum identity at the amino acid level is 99% (ORF29, small sub-unit terminase) (Table 2). Twenty and 22 ORFs out of 37 (54% and 59% of ORFs, respectively) from $\phi$APCM01 share more than 90% identity at the amino acid level with M102AD and M102, respectively. ORF29 is also close to ORF30 of phage M102 with 93% identity at the amino acid level; this ORF is absent from M102AD genome.

**Comparison of phage $\phi$APCM01 endolysins to other streptococcal phage endolysins**

Phages M102 and M102AD endolysins (ORF19 and ORF20) were shown to be 100% identical and to share similarity with other streptococcal endolysins [18]. Interestingly, ORF19 and ORF20 of $\phi$APCM01 are not identical to the corresponding ORFs of phages M102 and M102AD, and share 93.7% and 88.3% identity at the amino acid level, respectively (Table 2). S. mutans phage endolysins were then compared to other streptococcal phages which gave the closest BLAST identity values, and a phylogeny of these phages was established based on ORF19 (Fig 6A) and ORF20 (Fig 6B). In both cases, S. mutans phages constitute a distinct group from the other Streptococcus species. Based on ORF19 phylogeny, S. mutans phages are closer to S. agalactiae phage than to other streptococcal phages (Fig 6A). The phylogeny based on ORF20 could not relate S. mutans phages to any particular Streptococcus species (Fig 6B).

**Discussion**

S. mutans is the leading cause of dental caries worldwide and is considered to be the most cariogenic of all of the oral streptococci. Very little is known about S. mutans lytic phages. To our knowledge only two S. mutans phages, M102 and M102AD, have been sequenced to date [18, 19]. Phage M102 was isolated in 1988 in France [33], and M102AD came from a M102 batch
A New Phage against *S. mutans* Biofilm

(a)

![Graph showing OD at 650nm vs quantity of phage added (log pfu/well)]

(b)

![Graph showing log cfu/ml vs quantity of phage added (log pfu/well)]
kept at the University of Maryland which proved to be genetically different from the original phage M102 after genome comparison of the two phages [18]. Two other S. mutans phages have also been partially characterized in the University of Maryland, phages e10 and f1 [20]. A paper from the late 70’s also relates the presence of prophage inducible with mitomycin C in the genome of some S. mutans strains [34]. The scarcity of data on S. mutans phages is probably due to the difficulty to isolate phages from oral cavity samples. In the current study, only one phage, φAPCM01, was isolated from screening 85 saliva samples. Two other studies aiming at isolating phages against oral pathogens failed to isolate S. mutans phages [35, 36]. This could possibly be due to the low frequency of these phages in nature or, more probably, to their narrow host range. φAPCM01 isolated in the present study only targeted S. mutans strain DPC6143 out of the 17 tested strains. The fact φAPCM01 targets this strain is of importance as this strain is serotype e, which is the second more present S. mutans serotype in the oral cavity after serotype c [37]. Phages M102, M102AD, e10 and f1 also proved to have a narrow host range. In addition, these phages appear to be serotype-specific, although not all strains of the same serotype are sensitive to a given phage [18, 20], which was the case for φAPCM01. Indeed, the strain targeted by φAPCM01 was serotype e, and other serotype e strains tested in the present study were not sensitive to the phage. The sensitivity to phage φAPCM01 of other S. mutans strains, especially of serotype c and e, should be examined to further elucidate this

Fig 4. Effect of phage φAPCM01 on a 48 h-biofilm formed by S. mutans DPC6143, after 24 h (■) and 48 h (▲) of contact between phage and biofilm. (a) Biofilm metabolic activity was assessed by OD492nm measures after treatment with XTT supplemented with menadione. Experiments were performed in 96-well microplates, and each condition was tested in 8 wells of the microplate. (b) Bacterial counts in biofilms were performed in triplicate after contact with the phage. *p<0.05; **p<0.01; ***p<0.001. Error-bars indicate standard deviation.

doi:10.1371/journal.pone.0138651.g004

Fig 5. Genomic organization of φAPCM01 compared with that of phages M102 and M102AD. Each arrow represents an ORF, with the colour representing the putative function of the encoded protein indicated on the right. Percent amino acid identity between adjacent genomes is colour coded as outlined to the left.

doi:10.1371/journal.pone.0138651.g005
Table 2. ORFs of phage $\Phi$APCM01: putative functions and identity comparison to phages M102 and M102AD ORFs.

| ORF  | Start position | Stop position | Size (aa) | Molecular mass (kDa) | pI | Putative function | M102AD | M102 | Best match (% amino acid identity) | E-value |
|------|----------------|---------------|-----------|----------------------|----|-------------------|--------|------|-----------------------------------|---------|
| ORF1 | 179            | 547           | 122       | 14.4                 | 9.62 | Endonuclease      | ORF1 M102AD (91.8%, 122/122) | 6.0E-88 | ORF1 M102 (92.62%, 122/122) | 3.0E-88 |
| ORF2 | 563            | 907           | 114       | 13.3                 | 5.87 | Terminase, small subunit | ORF2 M102AD (99.11%, 112/114) | 6.0E-83 | ORF2 M102 (99.11%, 112/114) | 6.0E-83 |
| ORF3 | 894            | 2768          | 624       | 71.4                 | 5.25 | Terminase, large subunit | ORF3 M102AD (95.67%, 624/624) | 0.0E +00 | ORF3 M102 (95.51%, 624/624) | 0.0E +00 |
| ORF4 | 2970           | 3914          | 314       | 35.3                 | 5.58 | Portal protein    | ORF4 M102AD (94.9%, 314/314) | 0.0E +00 | ORF4 M102 (97.13%, 314/314) | 0.0E +00 |
| ORF5 | 3911           | 4813          | 300       | 32.4                 | 4.18 | Clp protease-like protein | ORF5 M102AD (93.33%, 300/300) | 0.0E +00 | ORF5 M102 (92.33%, 300/300) | 0.0E +00 |
| ORF6 | 4834           | 5970          | 378       | 41.0                 | 5.01 | Capsid protein    | ORF6 M102AD (95.77%, 378/378) | 0.0E +00 | ORF6 M102 (97.62%, 378/378) | 0.0E +00 |
| ORF7 | 6013           | 6324          | 103       | 11.7                 | 4.36 | DNA packaging     | ORF7 M102AD (96.12%, 103/103) | 2.0E-72 | ORF7 M102 (97.09%, 103/103) | 1.0E-73 |
| ORF8 | 6321           | 6665          | 114       | 13.3                 | 9.17 | Head-tail joining protein | ORF8 M102AD (92.98%, 114/114) | 3.0E-78 | ORF8 M102 (92.11%, 114/114) | 2.0E-77 |
| ORF9 | 6658           | 7050          | 130       | 15.0                 | 6.44 | Tail protein      | ORF9 M102AD (96.92%, 130/130) | 5.0E-95 | ORF9 M102 (95.35%, 129/130) | 3.0E-93 |
| ORF10| 7034           | 7390          | 118       | 13.3                 | 4.35 | Tail protein      | ORF10 M102AD (97.46%, 118/118) | 2.0E-83 | ORF10 M102 (94.07%, 118/118) | 2.0E-81 |
| ORF11| 7408           | 8085          | 225       | 24.0                 | 5.55 | Major tail protein | ORF11 M102AD (95.09%, 224/225) | 9.0E-154 | ORF11 M102 (97.32%, 224/225) | 3.0E-164 |
| ORF12| 8263           | 13419         | 518       | 67.1                 | 9.73 | Tape-measure protein | ORF12 M102AD (90.14%, 1734/1718) | 0.0E +00 | ORF12 M102 (90.83%, 1734/1718) | 0.0E +00 |
| ORF13| 13419          | 14945         | 508       | 57.4                 | 5.73 | Tail protein      | ORF13 M102AD (92.72%, 508/508) | 0.0E +00 | ORF13 M102 (92.52%, 508/508) | 0.0E +00 |
| ORF14| 14942          | 17110         | 722       | 81.3                 | 5.01 | Receptor binding protein | ORF14 M102AD (95.26%, 718/722) | 0.0E +00 | ORF14 M102 (94.99%, 718/722) | 0.0E +00 |
| ORF15| 17100          | 18857         | 585       | 64.7                 | 5.22 | Structural protein | ORF15 M102AD (87.69%, 585/585) | 0.0E +00 | ORF15 M102 (87.52%, 585/585) | 0.0E +00 |
| ORF16| 18880          | 19383         | 167       | 18.8                 | 5.09 | unknown           | ORF16 M102AD (88.62%, 167/167) | 3.0E-113 | ORF16 M102 (88.02%, 167/167) | 2.0E-112 |
| ORF17| 19401          | 19673         | 90        | 10.6                 | 8.85 | unknown           | ORF17 M102AD (98.89%, 90/90) | 3.0E-63 | ORF17 M102 (98.89%, 90/90) | 3.0E-63 |
| ORF18| 19670          | 20137         | 155       | 16.8                 | 5.89 | Holin             | ORF18 M102AD (89.68%, 155/155) | 1.0E-88 | ORF18 M102 (89.68%, 155/155) | 1.0E-88 |
| ORF19| 20153          | 20971         | 272       | 29.7                 | 5.16 | Lysozyme          | ORF19 M102AD (93.77%, 273/272) | 0.0E +00 | ORF19 M102 (93.77%, 273/272) | 0.0E +00 |
| ORF20| 20971          | 21486         | 171       | 18.7                 | 6.05 | Endolysin         | ORF20 M102AD (88.3%, 171/171) | 2.0E-114 | ORF20 M102 (88.3%, 171/171) | 2.0E-114 |
| ORF21| 21822          | 22601         | 259       | 30.0                 | 8.89 | Replisome organizer | ORF21 M102AD (76.84%, 272/259) | 6.0E-160 | ORF21 M102 (77.21%, 272/259) | 7.0E-161 |

(Continued)
| ORF  | Start position | Stop position | Size (aa) | Molecular mass (kDa) | pI | Putative function | M102AD | M102 |
|------|----------------|---------------|-----------|---------------------|----|-------------------|--------|------|
| ORF22| 23023          | 23781         | 252       | 29.3                | 8.68| DNA replication protein | ORF22 M102AD (90.87%, 252/252) | 2.0E-164 |
| ORF23| 23781          | 23984         | 67        | 8.0                 | 9.99| unknown            | ORF23 M102AD (88.06%, 67/67) | 2.0E-41  |
| ORF24| 23981          | 24133         | 50        | 6.1                 | 9.87| unknown            | ORF24 M102AD (82%, 50/50)  | 1.0E-29  |
| ORF25| 24144          | 24392         | 82        | 9.2                 | 4.15| unknown            | ORF25 M102AD (81.46%, 82/82) | 1.0E-54  |
| ORF26| 24402          | 25190         | 262       | 29.9                | 5.36| Single-strand annealing protein | ORF26 M102AD (83.4%, 235/262) | 3.0E-145 |
| ORF27| 25205          | 26134         | 309       | 35.6                | 8.12| unknown            | ORF27 M102AD (89.43%, 265/309) | 7.0E-159 |
| ORF28| 26135          | 26431         | 98        | 11.4                | 10.05| unknown           | ORF28 M102AD (91.64%, 98/98) | 4.0E-64  |
| ORF29| 26561          | 26905         | 114       | 13.6                | 9.66| unknown            | ORF29 M102AD (80.43%, 92/94) | 2.0E-51  |
| ORF30| 26993          | 27277         | 94        | 10.9                | 9.87| unknown            | ORF29 M102AD (80.43%, 92/94) | 2.0E-51  |
| ORF31| 27639          | 27992         | 117       | 13.5                | 5.02| unknown            | ORF31 M102AD (73.12%, 114/114) | 4.0E-48  |
| ORF32| 27985          | 28212         | 75        | 9.1                 | 9.91| unknown            | ORF32 M102AD (89.33%, 74/75) | 2.0E-48  |
| ORF33| 28218          | 28613         | 131       | 15.3                | 9.89| unknown            | ORF33 M102AD (80.92%, 131/131) | 1.0E-87  |
| ORF34| 28620          | 29015         | 131       | 15.2                | 7.95| Single-stranded DNA-binding protein | ORF34 M102AD (93.13%, 131/131) | 4.0E-90  |
| ORF35| 29030          | 29722         | 230       | 27.2                | 9.45| Holliday junction resolvase | ORF35 M102AD (75.71%, 140/230) | 3.0E-80  |
| ORF36| 29715          | 29912         | 65        | 7.2                 | 7.78| unknown            | ORF36 M102AD (75.35%, 65/65) | 5.0E-81  |
| ORF37| 30297          | 30641         | 114       | 13.3                | 5.05| unknown            | ORF37 M102AD (89.47%, 114/114) | 2.0E-71  |

Table 2. (Continued)
Adsorption of M102 phage to S. mutans cells depends on the type of the glucose side chain of the rhamnose-glucose-polysaccharides which constitute the receptor for phage M102 [38]. Moreover CRISPR sequences matching the S. mutans phage M102 genome were detected in some S. mutans strains, indicating a bacterial resistance mechanism to this particular type of phage [39, 40]. Other phage resistance systems also exist and are frequently discovered, like the recent bacteriophage exclusion system BREX [41]. All these factors may make it more difficult to find appropriate S. mutans strains with which to isolate virulent phages.

Like the four other reported S. mutans phages, ɸAPCM01 belongs to the Siphoviridae family. Its head and tail dimensions are in accordance with that of the other S. mutans phages [18, 20]. The ɸAPCM01 genome (31,075 bp) is slightly smaller than that of phage M102 (31,147 bp) [19] and bigger than that of phage M102AD (30,664 bp) [18]. ɸAPCM01 displays 85% nucleotide identity with M102 and M102AD and differs in that it has a reduced number of ORFs, albeit with an additional ORF31 specific to its genome. None of its predicted proteins are identical to those of the two previously sequenced phages. The fact that this new S. mutans phage is so closely related to existing S. mutans phage begs the question of the origin and evolution of these phages, and of the population structure. As observed for phage M102AD, it seems

![Molecular phylogenetic analysis by Maximum Likelihood method of endolysins in S. mutans phage ɸAPCM01. Comparison of ORF19 (a) and ORF20 (b) of ɸAPCM01 to other endolysins in streptococcal phages. Numbers indicate branches support based on 1000 bootstrap replications.](https://doi.org/10.1371/journal.pone.0138651.g006)
that the evolution of phage \( \Phi \)APCM01 genome is due to point mutations, and to the deletion and acquisition of genes [18], with no certainty regarding the frequency and nature of events causing those modifications. As the number of available \( S. mutans \) phage genomes is so limited a phylogenetic explanation of these events is not yet possible. We attempted to compare \( S. mutans \) phages to other phages by comparing their endolysins (ORF19 and ORF20). The \( \Phi \)APCM01 endolysin encoded by ORF19 is related to endolysins from different \( S. agalactiae \) phages. This is congruent with the observation previously made for phage M102AD where the endolysin shares 49% of its amino acids with \( S. agalactiae \) phage B30 endolysin [18]. An increased effort in isolating and sequencing more \( S. mutans \) phages will be required for a better understanding of the phage population structure, taxonomy and evolution [42]. The closeness of these three phage genomes isolated in different countries and almost 30 years apart strongly suggests an evolution from a common ancestor, and the existence of a cohesive population of \( S. mutans \) phages where genetic modification events occur at a very low rate.

Phage therapy is increasingly considered as a viable alternative for the treatment and control of pathogenic bacteria [43]. To date, the antimicrobial potential of \( S. mutans \) phage has not been extensively studied. In this study we tested the ability of \( \Phi \)APCM01 to reduce \( S. mutans \) growth and biofilm formation. Phage \( \Phi \)APCM01 was proven to be highly lytic with a burst size of \(~44\) against \( S. mutans \) strain DPC6143. Phage \( \Phi \)APCM01 also showed a lack of lysogenic properties with an efficiency of lysogeny of less than 0.03%, confirmed by the absence of a lysogeny module in its genome. If the colonies growing on phage-seeded plates were considered as bacteriophage-insensitive mutants (BIMs) [44], the lysogeny assay could also indicate that the frequency of BIMs is extremely low (less than 0.03%) in the presence of \( \Phi \)APCM01. These criteria make phage \( \Phi \)APCM01 a suitable candidate for phage therapy. \( \Phi \)APCM01 efficiently reduced the growth of \( S. mutans \) by at least 5 log cfu/ml in laboratory broth, and by at least 3 log cfu/ml in artificial saliva supplemented with sucrose. The latter ability is of great interest as it is closer to the real conditions of contact between \( S. mutans \) and its phages. It has been shown that the combination of saliva, sucrose water and nutrients had synergistic effects on \( S. mutans \) growth and long-term colonization [45]. Based on the results of the current study, the addition of phages could help in reducing the colonization of teeth surface by \( S. mutans \). This is particularly true in regard to the ability of \( \Phi \)APCM01 to reduce \( S. mutans \) biofilm in a model system after a minimum 24 h of contact. The metabolic activity of the biofilm was significantly reduced, and the number of live cells decreased by at least 5 log cfu/ml with phage doses of at least \( 10^5 \) pfu/well. After 48 h of contact with phage, the reduction of the metabolic activity of the biofilm did not systematically come with a reduction in the numbers of cells, which remained essentially stable. This indicates the prolonged control of the biofilm by the phage in time. The decrease in the metabolic activity of the biofilm could be due to the exhaustion of nutrients in the medium even if no significant differences in the control were visible after 48 h. To accurately explain the metabolic activity of the biofilm multiparametric measurements would need to be used as previously performed for \( S. mutans \) biofilms [46]. The reduction of \( S. mutans \) growth and biofilm formation has successfully been tested by the use of other antimicrobial agents such as essential oils and bioactive fractions [47], bacteriocins [48], commensal bacteria [49] and probiotic bacteria [50]. Combining these approaches with the use of phage \( \Phi \)APCM01 could compensate for the narrow host range of this phage at the current stage of investigation, and thus could increase the chances to prevent the development of \( S. mutans \) biofilm and caries formation. The combination of \( \Phi \)APCM01 with other \( S. mutans \) phages is also of utmost importance as phage cocktails have proven to be more efficient [51] because they limit the risk of bacterial adaptation and the emergence of resistance [52]. The combination of different phages would also permit to extend the host range of the phage cocktail and thus would improve its efficiency.
In conclusion, while the narrow host range is a significant disadvantage, the newly isolated phage \( \Phi \)APCM01 has promising antimicrobial properties, such as the ability to reduce \( S. \) mutans growth and biofilm formation. Its use in combination with other phages and antimicrobial agents can now be considered for future potential clinical use.

Acknowledgments

This publication has emanated from research conducted with the financial support of Science Foundation Ireland (SFI) under Grant Number SFI/12/RC/2273. The authors thank all the volunteers involved in this study. The authors would like to thank Dr Jennifer Mahony, Dr Eoghan Casey and Brian McDonnell for their help and advice. The authors also thank Marie-Noelle McSweeney and Juliette Bougnon for their help.

Author Contributions

Conceived and designed the experiments: MD CH RPR SRS. Performed the experiments: MD EDH HN RS. Analyzed the data: MD EDH FJC HN. Contributed reagents/materials/analysis tools: HN. Wrote the paper: MD HN FJC EDH CH RPR.

References

1. Nasidze I, Li J, Quinque D, Tang K, Stoneking M. Global diversity in the human salivary microbiome. Genome Res. 2009; 19(4): 636–43. doi: 10.1101/gr.084616.108 PMID: 19251737.
2. Pride DT, Salzman J, Haynes M, Rohwer F, Davis-Long C, White RA 3rd, et al. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. ISME journal. 2012; 6(5): 915–26. doi: 10.1038/ismej.2011.169 MEDLINE: PMID: 22158393.
3. Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, Naqvi A, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS pathog. 2010; 6(1): e1000713. doi: 10.1371/journal.ppat.1000713 PMID: 20072605.
4. Moteği M, Takagi Y, Yonezawa H, Hanada N, Terajima J, Watanabe H, et al. Assessment of genes associated with \( S. \) mutans biofilm morphology. Appl Environ Microbiol. 2006; 72(9): 6277–87. doi: 10.1128/aem.00614-06 PMID: 16957255.
5. Ahn SJ, Ahn SJ, Wen ZT, Brady LJ, Burme RA. Characteristics of biofilm formation by \( S. \) mutans in the presence of saliva. Infect Immun. 2008; 76(9): 4259–68. doi: 10.1128/iai.00422-08 PMID: 18625741.
6. Klein MI, Hwang G, Santos PHS, Campanella OH, Koo H. \( S. \) mutans-derived extracellular matrix in cariogenic oral biofilms. Frontiers in cellular and infection microbiology. 2015; 5. doi: 10.3389/fcimb.2015.00010 PMID: WOS:000349282700001.
7. Banas JA. Virulence properties of \( S. \) mutans. Front Biosci. 2004; 9: 1267–77. PMID: 14977543.
8. Parasion S, Kwiatek M, Gryko R, Mлизk L, Malm A. Bacteriophages as an alternative strategy for fighting biofilm development. Polish journal of microbiology / Polskie Towarzystwo Mikrobiologow = The Polish Society of Microbiologists. 2014; 63(2): 137–45. PMID: 25115107.
9. Endersen L, O’Mahoney J, Hill C, Ross RP, McAuliffe O, Coffey A. Phage therapy in the food industry. Annu Rev Food Sci Technol. 2014; 5(1): 327–49. doi: 10.1146/annurev-food-030713-092415.
10. Lu TK, Koens MS. The next generation of bacteriophage therapy. Curr Opin Microbiol. 2011; 14(5): 524–31. doi: 10.1016/j.mib.2011.07.028 PMID: 21868281.
11. Alemayehu D, Casey PG, McAuliffe O, Guineane CM, Martin JG, Shanahan F, et al. Bacteriophages \( \Phi \)MR299-2 and \( \Phi \)NH-4 can eliminate \textit{Pseudomonas aeruginosa} in the murine lung and on cystic fibrosis lung airway cells. mBio. 2012; 3(2): e00029–12. doi: 10.1128/mBio.00029-12 PMID: 22396480.
12. Maura D, Galtier M, Le Bouguenec C, Debarbieux L. Virulent bacteriophages can target O104:H4 enterohaemagglutinin \textit{Escherichia coli} in the mouse intestine. Antimicrob Agents Chemother. 2012; 56 (12): 6235–42. doi: 10.1128/AAC.00602-12 PMID: 23006754.
13. Meader E, Mayer MJ, Steverding D, Carding SR, Narbad A. Evaluation of bacteriophage therapy to control \textit{Clostridium difficile} and toxin production in an in vitro human colon model system. Anaerobe. 2013; 22: 25–30. doi: 10.1016/j.anaerobe.2013.05.001 PMID: 23685029.
14. Chhibber S, Gupta P, Kaur S. Bacteriophage as effective deconcentrating agent for elimination of MRSA from anterior nares of BALB/c mice. BMC Microbiol. 2014; 14: 212. doi: 10.1186/s12866-014-0212-8 PMID: 25112504.

15. Paisano AF, Spira B, Cai S, Bombana AC. In vitro antimicrobial effect of bacteriophages on human dentin infected with Enterococcus faecalis ATCC 29212. Oral Microbiol Immunol. 2004; 19(5): 327–30. doi: 10.1111/j.1399-302x.2004.00166.x PMID: 15327646.

16. Machuca P, Daille L, Vines E, Berrocal L, Bittner M. Isolation of a novel bacteriophage specific for the periodontal pathogen Fusobacterium nucleatum. Appl Environ Microbiol. 2010; 76(21): 7243–50. doi: 10.1128/aem.0135-10 PMID: 20851973.

17. Phee A, Bondy-Denomy J, Kishen A, Basrani B, Azarpazhooh A, Maxwell K. Efficacy of bacteriophage treatment on Pseudomonas aeruginosa biofilms. J Endod. 2013; 39(3): 364–9. doi: 10.1016/j.joen.2012.10.023 PMID: 23402508.

18. Delisle AL, Guo M, Chalmers NJ, Barak GJ, Rousseau GM, Moineau S. Biology and genome sequence of Streptococcus mutans phage M102AD. Appl Environ Microbiol. 2012; 78(7): 2264–71. doi: 10.1128/aem.07726-11 PMID: 22287009.

19. Van Der Ploeg JR. Genome sequence of Streptococcus mutans bacteriophage M102. FEMS microbiology letters. 2007; 275(1): 130–8. doi: 10.1111/j.1574-6968.2007.00873.x PMID: 17711456.

20. Delisle AL, Rostkowski CA. Lytic bacteriophages of Streptococcus mutans. Curr Microbiol. 1993; 27(3): 163–7. doi: 10.1007/bf01576015 PMID: 23835749.

21. Shibata Y, Ozaki K, Seki M, Kawato T, Tanaka H, Nakano Y, et al. Analysis of loci required for determination of serotype antigenicity in Streptococcus mutans and its clinical utilization. Journal of clinical microbiology. 2003; 41(9): 4107–12. doi: 10.1128/jcm.41.9.4107–4112.2003 PMID: 12958233.

22. Casey E, Mahony N, Neve H, Noben J-P, Bello FD, van Sinderen D. Genome and proteome analysis of bacteriophage Ld1 reveals the existence of a novel phage group infecting Lactobacillus delbrueckii subsp. lactis. Appl Environ Microbiol. 2014; 81(4): 1319–26. doi: 10.1128/aem.03413-14.

23. Broussard Gregory W, Oldfield Lauren M, Villanueva Valerie M, Lunt Bryce L, Shine Emilee E, Hatfull Graham F. Integration-Dependent Bacteriophage Immunity Provides Insights into the Evolution of Genetic Switches. Mol Cell. 2013; 49(2): 237–48. doi: http://dx.doi.org/10.1016/j.molcel.2012.11.012 PMID: 23246436.

24. Baron F, Cochet M-F, Ablain W, Grosset N, Madec M-N, Gonnet F, et al. Rapid and cost-effective method for micro-organism enumeration based on miniaturization of the conventional plate-counting technique. Lait. 2006; 86(3): 251–6.

25. Boland AB, Buhr K, Giannouli P, van Ruth SM. Influence of gelatin, starch, pectin and artificial saliva on the release of 11 flavour compounds from model gel systems. Food Chem. 2004; 86(3): 401–11. http://dx.doi.org/10.1016/j.foodchem.2003.09.015.

26. Tunney MM, Ramage G, Field TR, Moriarty TF, Storey DG. Rapid colorimetric assay for antimicrobial susceptibility testing of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2004; 48(5): 1879–81. PMID: 15105149.

27. Delcher AL, Harmon D, Kasif S, White O, Salzberg SL. Improved microbial gene identification with GLIMMER. Nucleic acids research. 1999; 27(23): 4636–41. PMID: 10556321.

28. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, et al. The RAST Server: rapid annotations using subsystems technology. BMC Genomics. 2008; 9: 75. doi:10.1186/1471-2164-9-75 PMID: 18261238.

29. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic acids research. 1997; 25(17): 3389–402. PMID: 9254694.

30. Jones DT, Taylor WR, Thornton JM. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci. 1992; 8(3): 275–82. PMID: 1633570.

31. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013; 30(12): 2725–9. doi: 10.1093/molbev/mst197 PMID: 24132122.

32. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985; 39(4): 783–91. doi: 10.2307/2408679.

33. Armayu E, Bousque JL, Boue D, Tiraby G. Isolation of lytic bacteriophages for Streptococcus mutans and Streptococcus sobrinus. J Dent Res. 1998; 67: 121.

34. Higuchi M, Rhee GH, Araya S, Higuchi M. Bacteriophage deoxyribonucleic acid-induced mutation of Streptococcus mutans. Infect Immun. 1977; 15(3): 938–44. PMID: 870435.

35. Bachrach G, Leizerovici-Zigmond M, Zlotkin A, Naor R, Steinberg D. Bacteriophage isolation from human saliva. Lett Appl Microbiol. 2003; 36(1): 50–3. PMID: 12485342.
36. Hitch G, Pratten J, Taylor PW. Isolation of bacteriophages from the oral cavity. Lett Appl Microbiol. 2004; 39(2): 215–9. doi: 10.1111/j.1472-765X.2004.01565.x PMID: 15242464
37. Nakano K, Ooshima T. Serotype classification of Streptococcus mutans and its detection outside the oral cavity. Future Microbiol. 2009; 4(7): 891–902. doi: 10.2217/fmb.09.64 PMID: 19722842.
38. Shibata Y, Yamashita Y, van der Ploeg JR. The serotype-specific glucose side chain of rhamnose-glucose polysaccharides is essential for adsorption of bacteriophage M102 to Streptococcus mutans. FEMS microbiology letters. 2009; 294(1): 68–73. doi: 10.1111/j.1574-6968.2009.01546.x PMID: 19493010.
39. van der Ploeg JR. Analysis of CRISPR in Streptococcus mutans suggests frequent occurrence of acquired immunity against infection by M102-like bacteriophages. Microbiol. 2009; 155(Pt 6): 1966–76. doi: 10.1099/mic.0.027508–0 PMID: 19383692.
40. Serbanescu MA, Cordova M, Krastel K, Flick R, Beloglazova N, Latos A, et al. Role of the Streptococcus mutans CRISPR-Cas systems in immunity and cell physiology. J Bacteriol. 2009; 197(4): 749–61. doi: 10.1128/JB.02333-14 PMID: 19493010.
41. van der Ploeg JR. Analysis of CRISPR in Streptococcus mutans suggests frequent occurrence of acquired immunity against infection by M102-like bacteriophages. Microbiol. 2009; 155(Pt 6): 1966–76. doi: 10.1099/mic.0.027508–0 PMID: 19383692.
42. Mahony J, van Sinderen D. Current taxonomy of phages infecting lactic acid bacteria. Frontiers in microbiology. 2014; 5: 7. doi: 10.3389/fmicb.2014.00007 PMID: 24478767.
43. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014; 4(1): 1–10. http://dx.doi.org/10.4161/viru.25991.
44. O’Flaherty S, Ross RP, Meaney W, Fitzgerald GF, Elbreki MF, Coffey A. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl Environ Microbiol. 2005; 71(4): 1836–42. doi: 10.1128/AEM.71.4.1836–1842.2005 PMID: PMC1082512.
45. Wu CC, Lin CT, Wu CY, Peng WS, Lee MJ, Tsai YC. Inhibitory effect of Lactobacillus salivarius on Streptococcus mutans biofilm formation. Molecular oral microbiology. 2014; 30(1): 16–26. doi: 10.1111/omi.12063 PMID: 25821503.
46. O’Connor EB, O’Riordan B, Morgan SM, Whelton H, O’Mullane DM, Ross RP, et al. A lacticin 3147 enriched food ingredient reduces Streptococcus mutans isolated from the human oral cavity in saliva. J Appl Microbiol. 2006; 100(6): 1251–60. doi: 10.1111/j.1365-2672.2006.02856.x PMID: 16696672.
47. Ly-Chatain MH. The factors affecting effectiveness of treatment in phages therapy. Frontiers in microbiology. 2014; 5: 51. doi: 10.3389/fmicb.2014.00051 PMID: 24600439.